Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge.

Tempus AI (TEM) has been drawing attention after recent share price moves, with the stock showing a gain over the past month but a decline across the past 3 months and year to date.

See our latest analysis for Tempus AI.

The recent 10.61% 1 month share price return contrasts with a 16.38% 3 month share price decline and a 19.79% year to date share price loss. Recent momentum therefore appears more like a short term bounce than a sustained trend, even though the 1 year total shareholder return of a 3.53% loss is less weak than the year to date picture.

If you are weighing Tempus AI against other healthcare technology names, it can help to scan a wider peer group using a focused list of 32 healthcare AI stocks

So with Tempus AI showing a recent bounce after earlier declines, a value score of 2, an intrinsic discount of about 51% and a price target still above the current US$50.02 level, is this a buying opportunity, or is the market already pricing in future growth?

Most Popular Narrative: 30.9% Undervalued

Tempus AI's most followed narrative points to a fair value of $72.40, comfortably above the last close at $50.02, putting the focus firmly on future execution.

Strong growth in testing volumes and biopharma partnerships positions Tempus AI for durable revenue gains, supported by differentiated technology and a growing data advantage.

Expanding clinical-genomic offerings and disciplined cost management drive improving profitability, while rising AI adoption and regulatory clarity provide long-term growth opportunities.

Read the complete narrative.

Want to see what underpins that higher fair value? The narrative leans on ambitious revenue compounding, margin lift, and a rich future earnings multiple that only select healthcare names usually command.

Result: Fair Value of $72.40 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, there is still clear risk if reimbursement for newer assays remains slow or if pharma data budgets tighten, which could challenge the current undervalued narrative.

Find out about the key risks to this Tempus AI narrative.

Another Angle on Valuation

Our DCF model estimates Tempus AI's fair value at about $102.50 per share, which is significantly higher than both the current $50.02 price and the $72.40 narrative fair value. That difference may indicate either potential upside or optimistic cash flow assumptions that you may want to stress test for yourself.